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Abstract 16 
Immune responses of Natural Killer (NK) cell are controlled by the balance between 17 
activating and inhibitory receptors, but the expression of these receptors varies 18 
between cells within an individual. Although NK cells are a component of the innate 19 
immune system, particular NK cell subsets expressing Ly49H are positively selected 20 
and increase in frequency in response to cytomegalovirus infection in mice. Recent 21 
evidence suggests that in humans certain NK subsets also have an increased 22 
frequency in the blood of HCMV infected individuals. However whether these 23 
subsets differ in their capacity of direct control of HCMV infected cells remains 24 
unclear. In this study we developed a novel in vitro assay to assess whether human 25 
NK cells subsets have differential abilities to inhibit HCMV growth and 26 
dissemination. NK cells expressing or lacking NKG2C did not display any differences 27 
when controlling viral dissemination. However, when in vitro expanded NK cells 28 
were used, cells expressing or lacking the inhibitory receptor Leukocyte 29 
Immunoglobulin-like receptor 1 (LIR1) were differentially able to control 30 
dissemination. Surprisingly, the ability of LIR1+ NK cells to control virus spread 31 
differed between HCMV viral strains, and this phenomenon was dependent on amino 32 
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acid sequences within the viral ligand UL18. Together, the results here outlined an in 33 
vitro technique to compare the long-term immune responses of different human NK 34 
cell subsets, and suggest, for the first time, phenotypically defined human NK cell 35 
subsets may differentially recognise HCMV infected. 36 
IMPORTANCE 37 
HCMV infection is ubiquitous in most populations, it is not cleared by the host after 38 
primary infection but persists for life. The innate and adaptive immune system 39 
controls the spread of virus, of which Natural Killer (NK) cells play a pivotal role. 40 
NK cells can respond to HCMV infection by rapid, short-term non-specific innate 41 
responses, but evidence from murine studies suggested NK cells may display a 42 
long-term, memory like responses to murine cytomegalovirus infection. In this study, 43 
we developed a new assay that examines human NK cell subsets that have been 44 
suggested to play a long-term memory-like response to HCMV infection. We show 45 
that changes in a HCMV viral protein that interacts with an NK cell receptor can 46 
change the ability of NK cell subsets to control HCMV while the acquisition odf 47 
another receptor has no effect on virus control.  48 
  49 
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Introduction 50 
Following primary human cytomegalovirus (HCMV) infection, lytic viral replication 51 
is controlled by the host immune response, which includes humoral (1, 2), innate (3, 4) 52 
and adaptive cellular immune responses (5-7). Despite this robust immune response 53 
the virus is still able to establish latency in myeloid progenitor cells (8, 9). Virus can 54 
reactivate when these cells differentiate to mature dendritic cells and as such the virus 55 
is able to persist for the life-time of the host. Primary infection of healthy 56 
immunocompetent individuals is most often asymptomatic, but the virus can cause 57 
severe diseases in immunocompromised transplant patients, immunocompromised 58 
patients with AIDS and the immune immature, particularly following in utero 59 
infection (10-14).  60 
 61 
Natural Killer (NK) cells are defined as a component of the innate immune system as 62 
they do not undergo somatic DNA rearrangements in order to express highly diverse 63 
antigen receptors in the same manner as B and T cells do (15). Instead NK cells 64 
express a wide variety of both activating and/or inhibitory receptors that are able to 65 
bind cellular ligands, some of which are normally expressed while others are induced 66 
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by infection or transformation (review in (16)). The balance between activating and 67 
inhibitory signals determines if an NK cell is activated and exerts an effector function 68 
or not. NK cells are implicated in control of herpesvirus infections, since individuals 69 
with rare NK cell defects have been shown to have difficulty controlling multiple 70 
different herpesvirus infections including HCMV(17, 18).  71 
 72 
In order to avoid this NK-cell response, HCMV encodes multiple proteins that 73 
modulate NK cell recognition of infected cells (19, 20). These NK evasion functions 74 
act by preventing cellular ligands binding to activating NK cell receptors (UL16, 75 
UL141, UL142, US18, US20, US9 (21-27) and miR-UL112 (21)), by expressing 76 
proteins which engage inhibitory NK cell receptors (UL18 (28), UL40 (20, 29)) and 77 
UL83 (30)), as well as modifying the structure of the immune synapse (UL135 (31)). 78 
 79 
However NK cells are not homogeneous, instead numerous different NK cell subsets 80 
exist within a given individual, since individual activating and inhibitory NK 81 
receptors are independently expressed in varied combinations on different cells. 82 
Murine studies have shown that the interaction between MCMV protein m157 and the 83 
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activating Ly49H receptor on murine NK cells leads to direct activation of NK cells 84 
and the control of MCMV disease (32). In contrast, the only known example of direct 85 
NK cell receptor binding with HCMV protein is the interaction of Leukocyte 86 
Immunoglobulin-like receptor 1 (LIR1, now commonly known as LILRB1), an 87 
inhibitory receptor that normally binds to human MHC class I molecules, with the 88 
HCMV protein UL18, a viral homologue of cellular MHC Class I-like molecules (33, 89 
34). Early work on the UL18 protein from HCMV strain AD169 suggested that it 90 
could enhance cytotoxic killing by a NK cell line against a EBV-infected 293 cell line 91 
target in chromium release assays (35), however these experiments did not consider 92 
the level of expression of LIR1 on NK cells. Subsequently Prod’homme et al (28) 93 
showed that the UL18 protein from HCMV strain AD169 actually lowered the 94 
short-term cytotoxic responses of NK cells, but only if they expressed LIR1 (LIR1+), 95 
leading to the conclusion that UL18 was an immunoregulatory protein that inhibited 96 
NK cells from clearing HCMV lytically infected cells (28) 97 
 98 
The activating C-type lectin receptor CD94/NKG2C, which normally binds to human 99 
HLA-E, can also bind with HCMV UL18 protein but with 1000 fold weaker affinity 100 
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than LIR1 (36). NKG2C+ NK cells have been shown to be preferentially expanded in 101 
HCMV-seropositive individuals (37-42). In vitro experiments demonstrated that 102 
HCMV can induce expansion of CD94/NKG2C+ NK cells (43), and these cells show 103 
enhanced cytotoxic responses against HCMV infected cells in the presence of 104 
HCMV-specific antibodies (44). Except UL18, no other HCMV viral ligand has been 105 
shown to bind directly with NKG2C/CD94. Moreover, although these reports support 106 
a strong correlation between an increase in NKG2C+ NK cells and HCMV serostatus 107 
(review in (16)), no report to date has determined whether the expression of NKG2C 108 
on NK cells, in the absence of HCMV seropositive donor serum (44), leads to better 109 
control of virus. 110 
 111 
So far, the interpretation of the role of LIR1 and NKG2C receptors has focused 112 
mainly on NK cell degranulation and cytotoxicity effector functions over short terms 113 
(4 to 6 hours) co-culturing of NK cells with infected target cells. However NK cells 114 
also secrete inflammatory cytokines, and can replicate after activation, and these can 115 
also influence virus replication (16). Thus longer term assessment of anti-viral 116 
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activity of NK cells and particularly of NK cell sub-populations, would be a valuable 117 
method to further understand the interaction of NK cells with HCMV infected cells. 118 
 119 
We have recently developed and utilized such a viral dissemination assay to examine 120 
the anti-viral activity of HCMV specific T cells (45). In this study, we have used a 121 
VDA in conjunction with co-culture of different NK cell subsets in order to compare 122 
their abilities to inhibit HCMV dissemination. In vitro expanded LIR1+ NK cells 123 
controlled the spread of laboratory HCMV strain AD169 less effectively than 124 
LIR1-non expressing (LIR1-) NK cells, in good agreement with the NK cell effector 125 
function analyses by Prod’homme et al (28). However, when low passage/clinical 126 
strains TB40/e and Merlin were used in the VDA, this was not the case. In fact, 127 
LIR1+ NK cells displayed stronger control of virus spreading compare to LIR1- NK 128 
cells, and this was observed in multiple different donors. Using the published crystal 129 
structure of  the LIR1-UL18/B2m complex to inform the generation of specific  130 
HCMV mutants, we identified three amino acids in the viral UL18 protein that were 131 
responsible for this phenomenon. Furthermore, using NK cell subsets expressing 132 
LIR1 and NKG2C, we demonstrated that LIR1, rather than NKG2C, plays the 133 
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dominant role in influencing the long-term responses of LIR1+ NK cells during 134 
HCMV dissemination.   135 
 10
Material and Methods 136 
Donor sample collection and isolation 137 
Heparinized peripheral blood was collected from healthy donors. HCMV serostatus 138 
was determined using an IgG enzyme-linked immunosorbent assay (Trinity Biotech, 139 
Didcot, United Kingdom). Ten HCMV-seronegative and five HCMV-seropositive 140 
donors were included in this study. Ethical approval involving donor peripheral blood 141 
was obtained from the Addenbrookes National Health Service Hospital Trust 142 
institutional review board (Cambridge Research Ethics Committee) for this study. 143 
Informed written consent was obtained from all recipients in accordance with the 144 
Declaration of Helsinki (LREC 97/092) 145 
 146 
Cell and viruses 147 
The Human Foreskin Fibroblast (HFF) cell line was obtained from a commercial 148 
company (Invitrogen, Paisley, UK) and was cultured in EMEM (Life Technologies) 149 
supplemented with 10% foetal calf serum (PAA, Linz, Austria), 100,000 IU/ml 150 
penicillin (Life Technologies), and 100 mg/ml streptomycin (Life Technologies) 151 
(MEM-10). The strains of HCMV used in these studies were AD169, AD169 with 152 
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UL18 ORF deleted (AD168-ΔUL18) (46), Merlin containing a GFP-UL32 fusion 153 
protein (Merlin) (47), Merlin-GFP- UL32 with UL18 ORF deletion (Merlin-ΔUL18), 154 
and TB40/e-GFP-UL32 (TB40/e, kind gift of Christian Sinzger). In addition the UL18 155 
sequence modified virus strains (AD169-UL18Merlin and Merlin-UL18AD169) were 156 
generated by recombineering as previously described (48) using primers listed in 157 
Table 1. The method used to generate the mutant virus isolates does not lead to the 158 
loss of US2-US6 HCMV genes. 159 
 160 
Sequencing of HCMV UL18 ORF 161 
DNA was extracted from HCMV infected fibroblasts using the DNeasy-Blood and 162 
Tissue Kit (Qiagen). 30-cycle PCR was performed to amplify viral UL18 ORF using 163 
forward primers shown in Table 1 and conditions as previously described (49). 164 
Samples were sequenced by Source Bioscience Sequencing Team, Cambridge UK. 165 
 166 
Preparation of in vitro expanded NK cells 167 
Fresh peripheral venous blood was obtained by venipuncture, performed by a trained 168 
phlebotomist. PBMC were isolated from fresh peripheral venous blood by Ficoll 169 
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Hypaque density gradient centrifugation (Axis-Shield, Oslo, Norway) as previously 170 
described (50). NK cells were purified from PBMC, using EasySep-Human NK cell 171 
enrichment kit (StemCell Technologies). In vitro expanded, activated NK cell lines 172 
(referred to as in vitro expanded NK cells) were then generated from ex-vivo NK cells 173 
by co-culturing with irradiated allogenic EBV transformed B cell lines and irradiated 174 
autologous PBMC using methods previously described (24). The cell lines were 175 
cultured in RPMI-10 (described earlier) with 25 IU/ml IL-2 (National Institute for 176 
Biological Standards and Controls) replenished every 5 days.  177 
 178 
Preparation of sorted NK cell subsets 179 
In vitro expanded NK cell lines were stained with mouse anti-human CD56–pacific 180 
blue (PB) or FITC (eBioscience UK), CD3–PerCP/Cy5.5 (Biolegend UK), 181 
LIR1/CD85j–phycoerythrin (PE) (Biolegend UK), and NKG2C-Allophycocyanin 182 
(APC)-antibodies (Biolegend UK). CD56+ CD3- NK cells were sorted into different 183 
populations using a FACSJazz cell sorter running FACS DIVA software (Becton 184 
Dickinson, UK). 185 
 186 
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CD107a degranulation assays 187 
K562 (1x106) or HCMV infected fibroblasts (overnight infection with TB40/e, 188 
MOI=5) were co-cultured with in vitro expanded NK cells at a ratio of 1:1 in 50μl 189 
RPMI-10 and incubated at 37°C and 5% CO2. Monensin (BioLegend) was added at 190 
1:1000 dilution after 1 hour co-incubation and further incubated for 4 hours at 37°C 191 
and 5% CO2. Cells were washed in PBS before staining with anti-human CD56 192 
(APC), CD3–FITC, and CD107a PerCP/Cy5.5 antibodies (Biolegend UK) before 193 
being analysed by flow cytometry using FACSCalibur (BD) running CellQuest 194 
software (BD). Results were analysed using FlowJo 7.6 (Tree Star Inc., OR, USA). 195 
 196 
CCL4 cytokines ELISAs 197 
In vitro expanded NK cells were co-cultured overnight with K562 or HCMV infected 198 
fibroblasts (overnight infection with TB40/e, MOI=5) using the method described 199 
earlier for CD107a assays, but without monensin. The co-cultures were left for 12 200 
hours before the supernatant was harvested and the CCL4 cytokine concentration was 201 
measured using an ELISA kit (R&D systems). 202 
 203 
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In vitro viral dissemination assay 204 
The ability of NK cell subsets (sorted based on differences in specific receptor 205 
expression) to control the spread of HCMV virus in vitro was measured. Allogeneic 206 
human foreskin fibroblasts (HFF) cells were seeded in a 24-well flat-bottom culture 207 
plates (LifeSciences, UK) to be 80-90% confluent when they were infected with virus 208 
at an MOI of 0.1 overnight. Rested in vitro expanded NK cells were harvested, 209 
washed, stained, sorted and resuspended in MEM-10 then added to the infected 210 
fibroblasts at NK cell: Fibroblast ratios of 1.25, 0.625 or 0.3125:1 in 1 ml MEM-10 211 
and incubated at 37°C and 5% CO2. Assessment of viral dissemination was 212 
performed at 9 days post incubation. GFP expression (TB40/e and Merlin) was 213 
detected by either fluorescent microscopy or flow cytometry. When HCMV AD169 214 
was used, fibroblasts were stained intracellularly with anti-CMV IE-AlexaFluor488 215 
antibody (Millipore) using Cell Fixation/ Permeabilization kit (An-Der-Grub 216 
BioResearch). Fibroblasts were fixed with 2% paraformaldehyde-PBS solution and 217 
analysed using flow cytometry as described earlier.  218 
Viral spread in each well was determined as a percentage of control wells lacking NK 219 
cells, using the equation: 220 
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([Experimental % of infected cells - background % of HFF only control] / [% of 221 
infected HFF control without NK cells - background % of HFF only control] ) x100 222 
 223 
Phylogenetic tree  224 
BioEdit Sequencing Alignment Editor was used for sequence analysis. The 225 
evolutionary phylogenetic trees were computed using Molecular Evolutionary 226 
Genetics Analysis (MEGA).  227 
 228 
Statistics 229 
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows 230 
(GraphPad Software, San Diego, CA). Probabilities were calculated with one way or 231 
two-way ANOVA paired Friedman test in the viral dissemination assay, assuming 232 
not-repeated measures. Standard T-test analysis was used to analyse the cytokine 233 
CCL4 release assay and CD107a degranulation assay. Results with p<0.05 were 234 
considered as significant. 235 
 236 
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Results 237 
Control of different strains of HCMV dissemination by in vitro expanded 238 
primary NK cell lines. 239 
We have previously developed an assay to measure T cell mediated anti-viral activity 240 
based on the inhibition of HCMV dissemination through a permissive fibroblast 241 
monolayer (51, 52). In addition a focal expression assay which is similar in concept to 242 
our viral dissemination assay (VDA) has recently been described by others (52) and 243 
used to examine anti-HCMV activity by NK cells (45). We wished to use our viral 244 
dissemination assay (VDA) to study the antiviral activity of different NK cell subsets, 245 
as defined by specific cell surface markers.  246 
 247 
In order to validate this approach, we used the VDA against different strains of 248 
HCMV to determine if in vitro expanded NK cells were able to control the spread of a 249 
high passage laboratory adapted (AD169) and low passage isolates of HCMV TB40/e 250 
and Merlin. The results clearly show that NK cells were able to prevent viral spread in 251 
an effector: target ratio (E:T) dependent fashion. This was visualised by fluorescent 252 
microscopy and quantified by flow cytometry, either by GFP if the virus expressed 253 
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GFP (Figure 1A) or by anti-HCMV IE antigen staining with a fluorescent antibody if 254 
it didn’t (Figure 1B).  255 
 256 
High passage strains such as AD169 lack multiple immune evasion genes. This 257 
renders AD169 infected cells more susceptible to NK cell mediated lysis as compared 258 
to low passage HCMV isolates such as TB40/e or Merlin, in short-term cytotoxicity 259 
assays (53, 54). In order to compare VDA results between different strains of virus, 260 
data for each virus was normalized against its own positive (HCMV infected HFF 261 
without NK cells) and negative (non-infected HFFs) controls. The positive control 262 
represents the maximal spread of the virus over the course of the assay, while the 263 
negative control is the background fluorescence .  264 
 265 
Across multiple donors, it was clear that the virus spread of AD169 (n=4) was 266 
significantly reduced compared to Merlin (n=9) and TB40/e (n=7), implying that 267 
polyclonally activated NK cells were significantly more efficient at controlling the 268 
spread of AD169 (Figure 1C). In addition, TB40/e was controlled less well than 269 
Merlin at the highest E:T ratio of 1.25:1. A similar trend was evident at the lower 270 
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ratios, although this was not statistically significant (Figure 1C). Importantly, NK 271 
cells still exerted some degree of control over Merlin as spread did not reach 100 % 272 
for any of the E:T ratios tested (Figure 1C). We also performed VDAs using in vitro 273 
expanded NK cells derived from either a HCMV seropositive or a seronegative donor 274 
(Figure 1D). No major differences were seen between the polyclonal NK cells from 275 
these donors, with cells from both being significantly more efficient at controlling the 276 
spread of AD169 than either TB40/e or Merlin. 277 
 278 
Taken together, these results demonstrate that, using this NK cell VDA, a 279 
low-passage isolate of HCMV (Merlin) was resistant to NK cell mediated control, 280 
while an isolate lacking NK immune evasion genes (AD169) was less resistant. 281 
Despite low-passage strains being more resistant to NK cell control, polyclonal NK 282 
cells did still exert some degree of control, indicating that this assay represented a 283 
useful method to study the anti-viral properties of different subsets of NK cells, as 284 
well as the ability of different HCMV isolates to affect NK cell recognition.  285 
 286 
Comparison of LIR1+ and LIR1- NK cell control of HCMV dissemination 287 
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The VDA was able to identify differences in the ability of NK cells to control 288 
different HCMV strains, we next wanted to use the assay to determine if certain NK 289 
cell subsets, as defined by surface expression of particular phenotypic markers, were 290 
more efficient at controlling HCMV infection. The HCMV MHC Class I homologue 291 
UL18 (specifically from strain AD169) has already been shown to decrease direct NK 292 
cell cytotoxic responses as it is able to bind the inhibitory receptor LIR1 present on 293 
some NK cell subsets (28). As such, AD169 should be less well controlled by LIR1+ 294 
NK cells (which would be inhibited by HCMV UL18 protein expression) as 295 
compared to LIR1- NK cells (which would not be inhibited by UL18 (28)). 296 
 297 
Primary in vitro expanded NK cell lines were generated from different donors, NK 298 
cells were sorted as CD3-CD56+ cells before sorting into subsets based on their LIR1 299 
expression, achieving >95% purity after sorting (Figure 2A). To ensure that the 300 
subsets maintained their effector functions, post-sorting cytotoxicity and cytokine 301 
secretion against the classic K562 target cells was examined (55). NK cell 302 
cytotoxicity was determined by CD107a degranulation assay and cytokine production 303 
was assessed by measuring CCL4 production, one of the earliest inflammatory 304 
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cytokines produced following NK cell activation (56). While the NK cell lines were 305 
capable of generating IFNγ against K562 target cells, the response was modest at 306 
between 20-30 pg/ml. The CCL4 response was more substantial at 400pg/ml 307 
and was also elicited by HCMV infected target cells, therefore we measured CCL4 308 
for all the subsets as it provided a better dynamic range in order to determine if 309 
cell sorting had caused differences in the sorted subsets. 310 
 311 
 Both LIR1+ and LIR1- subsets had a similar cytotoxic response and level of CCL4 312 
secretion to the unsorted NK cell line from which they were derived (Figure 2B). 313 
Thus NK cells maintain their cellular functions after sorting and also suggests that 314 
engagement of anti-LIR1 antibodies did not cause inhibition of LIR1+ NK cell 315 
effector functions. 316 
 317 
The LIR1+ and LIR1- NK cell subsets were then used in a VDA against AD169 318 
infected HFFs. As predicted, the results show that there was greater percentage of 319 
viral spread in the presence of LIR1+ NK cells as compared to LIR1- NK cells 320 
(Figure 2C). The VDA was also performed using HFFs infected with the low passage 321 
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HCMV strains TB40/e and Merlin. Surprisingly, different results were obtained. 322 
Against these strains, LIR1+ NK cells demonstrated more efficient virus control 323 
compared to the LIR1- NK cells (Figure 2D and E). The same results were observed 324 
for three independent donor NK cell lines tested (Figure 2C-E). Thus differences 325 
between HCMV strains can affect the ability of NK cell subsets to control virus 326 
spread.  327 
 328 
Deletion of HCMV UL18 ORF abolishes the differential controls mediated by 329 
LIR1+ and LIR1- NK cells  330 
We next investigated whether the above phenomenon (Figure 2C-E) was caused by 331 
the viral UL18 protein. If it was due to the interaction of UL18 on HCMV infected 332 
cells with LIR1 receptors on NK cells, the difference should be negated if a virus 333 
deleted for UL18, or a blocking antibody to LIR1, were used in these assays. While 334 
LIR1 blocking antibodies are available, they could deliver inhibitory signals through 335 
LIR1, and we were concerned that the antibody concentrations was maintained over 336 
the long period of this assay, as such we have determined the involvement of UL18 337 
by using UL18 deletion mutants of  both AD169 and Merlin. 338 
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 339 
VDA were conducted using HCMV AD169- ΔUL18 and Merlin-ΔUL18 viruses as 340 
well as their parental strains. As before, LIR1+ NK cells were less able to control the 341 
spread of AD169 compared to LIR1- NK cells; however when AD169-ΔUL18 was 342 
used, this difference was eliminated (Figure 3A). In donor 410, the LIR1- NK cells 343 
exhibit the same level of viral control for both AD169 and AD169-dUL18 virus 344 
however, the major change occurs with LIR1+ NK cells, which exert better control 345 
over AD169-dUL18 virus than AD169, in agreement with the other independent 346 
donors. In donor 319, we noted a discrepancy, that both LIR1+ and LIR1- cells 347 
exerted greater control when UL18 has been deleted in this experiment. However,  348 
it seems to be donor specific (donor to donor variation) rather than virus specific 349 
as it does not occur in other donors (405 for example), indicating that it is 350 
unlikely to be due to additional changes in the AD169-dUL18 strain. Nevertheless, 351 
although with donor 319 the AD169-dUL18 strain had a lower spread than 352 
expected in the presence of both LIR1+ and LIR1- NK cells, the two subsets did 353 
maintained the same pattern as the other donors (i.e. there were no significant 354 
differences between the subsets once UL18 was removed). Because of this, we 355 
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feel that the data support the conclusion that removal of UL18 from AD169 356 
allows better control by LIR1+ NK cells.  When HCMV strain Merlin was used, 357 
LIR1+ NK cells controlled virus spread better than LIR1- NK cells again 358 
independently verifying our previous observations (Figure 2). Similar with AD169, 359 
deletion of UL18 from this virus strain also resulted in the elimination of this 360 
difference (Figure 3B). The experiments were repeated using NK cells derived from 361 
four independent donors and in all but one donor the same pattern of results were 362 
observed (Figure 3A-B): donor 302 showed a significant difference between subsets 363 
when AD169-dUL18 was used (Figure 3A), while donor 405 showed a small but 364 
significant difference between the subsets when Merlin-ΔUL18 was used (Figure 3B). 365 
 366 
The results suggested that UL18 was responsible for the effects on LIR1+ and LIR1- 367 
NK cell control of viral dissemination, and further suggested that UL18 from different 368 
strains affected NK cell subsets in a different manner. The crystal structure of the 369 
UL18 protein interacting with LIR1 receptor has been determined by Yang et al (57) 370 
showing that the interactions occur between the α3 domain of UL18 and LIR1 371 
receptor (57). There are three sites of interactions between UL18 and LIR1, compared 372 
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with two sites between human MHC Class I and LIR1, which has been suggested as 373 
the reason for a 1000-fold higher binding affinity observed between UL18 and LIR1 374 
compared to MHC Class I (57).  375 
 376 
To investigate if strain-dependent sequence variability was responsible for the 377 
differences observed in LIR1+ NK cell control of HCMV dissemination, UL18 378 
sequences from the Genebank were identified and the amino acid sequences within 379 
the α3 region were aligned (Figure 3C). In this region, HCMV strains TB40/e and 380 
Merlin have a sequence of NKAPDD, while AD169 has DKVPED. These three 3 381 
amino acid differences (N/D, A/V and D/E) are located adjacent to the additional site 382 
of interaction with LIR1 proposed by Yang et al (57), which results in the increased 383 
binding affinity compared to the MHC1-LIR1 interaction. 384 
 385 
Although these amino acids have not been implicated in the direct interaction between 386 
UL18 and LIR (57), we hypothesized that they maybe of significance because 12 out 387 
of 13 unique UL18 sequences in the database have either amino acid sequences of 388 
NKAPDD or DKVPED (Figure 3B). We further constructed a 389 
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neighboring-phylogenic tree to analyse the similarity in the α3 domains between the 390 
HCMV viral strains (Figure 3D). The alignment shows that both the UL18 sequences 391 
from TB40/e and Merlin were closely related to each other, while the AD169 392 
sequence was located in a different cluster (Figure 3D). There were no differences 393 
between the α1 and α2 regions of UL18 proteins from these three viruses (not shown).  394 
 395 
UL18 sequence variability affects NK cell control of HCMV dissemination  396 
If the 3 amino acids identified in figure 3 were responsible for the differences 397 
observed in control of viral dissemination, mutating the UL18 from the sequence of 398 
one virus strain to the sequence of the other, should reverse the pattern of control 399 
observed with LIR1+ and LIR1- NK cells. Recombineering was used to mutate the 400 
AD169 sequence from DKVPED to the Merlin sequence NKAPDD 401 
(AD169-UL18Merlin) and a reciprocal mutation was made to Merlin sequence from 402 
NKAPDD to the AD169 sequence DKVPED (Merlin-UL18AD169), and mutant 403 
UL18 sequences verified by PCR amplification and sequencing (Figure 4A). These 404 
mutant viruses were used to infected human fibroblasts and VDA performed using 405 
LIR1+ and LIR1- NK cells derived from multiple independent donors. 406 
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 407 
As previously observed, LIR1+ NK cells from four different donors were less 408 
effective at controlling AD169 dissemination (Figure 4B, left column). However, 409 
when the three amino acids were mutated to the Merlin sequence the pattern of 410 
recognition was changed to that previously seen with Merlin virus, whereby LIR1+ 411 
NK cells controlled virus spread more effectively than LIR1- NK cells (Figure 4B, 412 
right column). Likewise, as before, LIR1+ NK cells from all donors were more 413 
effective at controlling Merlin dissemination than LIR1- NK cells (Figure 4C, left 414 
column), and the mutation of three amino acids within UL18 of Merlin to the AD169 415 
sequence reversed this pattern whereby LIR1+ NK cells controlled virus spread less 416 
effectively than LIR1- NK cells (Figure 4C, right column). Together these results 417 
suggest that LIR1 expressing NK cell subsets can differentially control HCMV, but 418 
that this ability can be altered by variation in the sequence of UL18, the viral ligand to 419 
the LIR1 receptor.  420 
 421 
NKG2C expressing NK cells influence the functional responses of NK cells but 422 
not the dissemination of HCMV 423 
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It has been suggested that receptors other than LIR1 may also influence the activity of 424 
NK cells against HCMV infected cells, in particular the activating receptor NKG2C. 425 
Numerous reports have shown strong correlation between the acquisition of HCMV 426 
infection and an increase in frequency of NKG2C-expressing NK cells in peripheral 427 
blood (37-43), and one report has suggested that NKG2C binds with UL18 at very 428 
low affinity (36). Although no reports to date have shown differential control between 429 
NKG2C+ and NKG2C- NK cells of HCMV in standard cytotoxic assays, one recent 430 
report does suggest that NKG2Cbright NK cells exhibits higher degranulation against 431 
target cells in the presence of serum containing HCMV-specific antibodies (44).  432 
 433 
We therefore investigated whether NKG2C+ NK cells mediated better control of 434 
HCMV in our viral dissemination assay. Since we had already shown that LIR1 435 
expression affected NK-mediated control of viral spread, cells were sorted into four 436 
subsets based on both LIR1 and NKG2C expression (Figure 5A). We also analysed 437 
activated NK cell lines with anti-NKG2A, NKG2C and LIR 1 in order to determine 438 
the distribution of the inhibitory NK cell receptor  NKG2A from four different 439 
donors (2 HCMV seropositive 2 HCMV seronegative). The results show that there 440 
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was no or negligible expression of inhibitory receptor NKG2A (HCMV 441 
seropositive 0.4% and 1.1%, HCMV seronegative 0% and 5%) cells and as such 442 
was unlikely to have a significant impact on the functional assay. 443 
 444 
 To ensure these subsets maintained their effector functions post-sorting, their 445 
cytotoxicity (CD107a degranulation) and cytokine secretion against K562 target cells 446 
was determined. Both LIR1+ NKG2C+ and LIR1- NKG2C+ NK cells degranulated 447 
significantly more strongly than the LIR1+ NKG2C- and LIR1- NKG2C- NK cells. 448 
i.e. NK cell subsets expressing the NKG2C activating receptor had higher cytotoxicity 449 
towards K562 target cells than subsets without NKG2C (Figure 5B, left), however, 450 
expression of LIR1 made little difference in this effector assay. The cytokine release 451 
assay showed no significant differences between any NK cell subsets  (Figure 5B, 452 
right). Interestingly, these results suggested that different NK cell effector 453 
mechanisms could be independently activated. 454 
 455 
The four NK cell subsets were also co-cultured with strain TB40/e infected target 456 
cells and CD107a and cytokine responses measured. All of the subsets displayed low 457 
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cytotoxicity against TB40/e-infected fibroblasts (Figure 5C, left), similar to previous 458 
studies using in vitro expanded NK cell lines (24, 53). In contrast, the cytokine release 459 
assay showed that although all subsets maintained their CCL4 production in response 460 
to TB40/e infected fibroblasts, however NKG2C+ NK cell subsets had significantly 461 
higher CCL4 secretion than NKG2C- subsets (p<0.05), irrespective of LIR1 462 
expression (Figure 5C, right). Together these results suggested that expression of 463 
NKG2C enhances CCL4 release by NK cells when interacting with TB40/e infected 464 
target cells, but the induction of cytokine release does not correlate with NK cell 465 
degranulation. 466 
 467 
The 4 NK subsets were also used simultaneously in a VDA (Figure 6) using NK cells 468 
from four independent donors. In good agreement with our earlier results, NK cell 469 
subsets with LIR1 expression, with or without NKG2C, resulted in a lower percentage 470 
of viral spread than cells without LIR1 (Figure 6A). This was observed across all the 471 
donors tested. However, when we compared the NKG2C+ NK cell subsets against 472 
NKG2C- NK cell subsets, with or without LIR1 expression, three out of four donors 473 
tested showed no difference in the degree of HCMV control (Figure 6B). In one donor, 474 
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the LIR1+NKG2C+ subset exerted worse control than LIR1+NKG2C- NK subset 475 
(Figure 6B, left column); while with another donor, LIR1-NKG2C+ NK subset 476 
exerted better control than LIR1-NKG2C- NK cells (Figure 6B, right column). 477 
However, taken together, we concluded that there is no clear difference in the degree 478 
of HCMV dissemination when NK cells express or lack NKG2C on their surface. 479 
  480 
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Discussion 481 
To date, ten HCMV gene products and one HCMV microRNA have been shown to 482 
interfere with NK cell immune responses, by disrupting both activating and inhibitory 483 
signaling to NK cells during HCMV lytic infection (19, 20).  Studies into the activity 484 
of NK cells in vitro against HCMV infected cells has predominantly focused on 485 
effector mechanisms such as cytokine production and cytotoxicity (28, 35). Moreover, 486 
although the frequency of NK cells expressing several NK receptors is associated 487 
with HCMV serostatus (37, 39, 58), enhancement in NK cell effector functions has 488 
only been demonstrated in the presence of anti-HCMV antibodies (41). Currently 489 
there is little in vitro evidence to suggest that these higher frequency NK cell subsets 490 
confer better control of HCMV in longer term culture.  491 
 492 
A viral dissemination assay that we had previously used to study CD8+ T cell 493 
responses (51) was established to test NK cell responses against fibroblasts lytically 494 
infected with HCMV. This was similar in concept to a recently published focal 495 
expansion assay (45), which was used to investigate the control of viral spread by NK 496 
cells during HCMV TB40/e infection, and the effect of deletion of known viral NK 497 
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immune evasion genes. This work concluded that NK cells can efficiently control 498 
HCMV transmission in different cell types and the UL16 viral protein contributes to 499 
the immune evasion of NK cells during HCMV transmission. The focal expansion 500 
assay and the viral dissemination assay are new methodological approaches employed 501 
for studying the longer term interaction between NK cells and HCMV infected cells 502 
in vitro. Compared with conventional NK cell cytotoxicity and degranulation assays, 503 
both focal expansion and viral dissemination assays aim to assess the longer-term 504 
control of NK cells on HCMV infection by indirectly measuring changes in the spread 505 
of virus in the presence of NK cells. While we did not investigate which NK cell 506 
effector mechanisms (either cytokine secretion or direct cell cytotoxicity or both) are 507 
effective at limiting growth and dissemination of HCMV in our VDA, it has been 508 
demonstrated by Wu et al (45) that during long-term co-incubation of NK cells with 509 
HCMV infected target cells, both direct cell contact and soluble factors like IFN γ are 510 
contributing factors to the control of dissemination (45). 511 
 512 
Our assay shows that NK cells can exert effector functions at an E:T ratio as low as 513 
0.3125:1, which is considerably lower and more physiological than short-term NK 514 
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cell cytotoxicity and degranulation assays, which often required an E:T ratio of 10:1 515 
and higher.  Our data support the hypothesis that NK cells control low passage 516 
strains such as Merlin less effectively than high passage laboratory mutants such as 517 
AD169; this is expected as AD169 is lacking several immune evasion genes (59, 60). 518 
TB40/e is known to contain a mixture of virus populations, including some that lack a 519 
functional UL141 (an established NK immune evasion gene) (53, 61), and also 520 
contains a non-functional UL40 gene (62). Thus it was interesting to note that the 521 
dissemination assay was also able to distinguish between NK cell control of infections 522 
with TB40/e and Merlin, underlining the advantages of working with defined strains 523 
that express a full complement of HCMV genes when characterizing viral 524 
pathogenesis.  525 
 526 
Importantly, our assay demonstrated for the first time that the ability of in vitro 527 
expanded, activated LIR1+ NK cells to inhibit viral dissemination differs from LIR1- 528 
NK cells, and was dependent on natural sequence variation within the ligands 529 
expressed by a viral strain. These strain differences are likely due to the differences in 530 
the binding kinetics exhibited by UL18 proteins from different HCMV strains to 531 
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LIR-1 (63, 64). Vales-Gomez et al demonstrated that a particular isolate of the UL18 532 
protein, Variant E, which has the identical amino acid sequences in the α3 region as 533 
strain Merlin UL18, showed a binding affinity that was at least 50 fold lower than the 534 
UL18 protein from AD169 (63). They also demonstrated that the UL18 protein of 535 
Variant E exhibited weaker inhibition against a LIR1-expressing transformed NK cell 536 
line as compared to UL18 derived from AD169 (63). A separate study carried out by 537 
Cerboni et al also showed that purified AD169 UL18 protein was able to inhibit 538 
cytotoxicity of the NKL cell line to a greater extent than UL18 protein from a clinical 539 
isolate, which again had the same α3 sequence found in strain Merlin (64). 540 
Interestingly the three amino acids that we identified as responsible for the differing 541 
abilities of NK cells to control dissemination, have recently been shown to be under 542 
positive selection in HCMV strains, towards the more inhibitory sequence (65), 543 
suggesting that the need to avoid activating NK cells can directly drive virus 544 
evolution. 545 
 546 
Given the above considerations, it seems likely that UL18 from both the Merlin and 547 
TB40/e strains have weaker affinity for LIR1, and as a result LIR1+ NK cells 548 
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received weaker inhibitory signals than from the AD169 strain, and as a result 549 
therefore were better at controlling HCMV dissemination. It is also possible that 550 
UL18 of TB40/e/Merlin also interacts with other NK receptors that leads to 551 
enhancement in NK cell function, which have yet to be identified. Alternatively, 552 
instead of inducing weaker inhibition signaling via LIR1, the UL18 protein of 553 
Merlin/TB40/e might cause a change in clustering of LIR1 receptor and ‘antagonize’ 554 
inhibitory signaling. This antagonistic ligand behavior had been suggested in certain 555 
peptide:MHC-KIR interactions between HCV and NK cells (66), although the 556 
mechanism has yet to be fully established.  557 
 558 
Lastly, we examined the effect of expression of the activating receptor NKG2C (67). 559 
An increase in the proportion of NKG2C+ NK cells is strongly associated with 560 
HCMV serostatus (37, 38, 40, 43, 68). However, there is as yet no evidence to suggest 561 
that the acquisition of NKG2C on NK cells without the presence of anti-HCMV 562 
antibodies confers a stronger immune response against HCMV infection. More 563 
recently, another study demonstrated that although HCMV seropositive patients 564 
receiving allogeneic stem cell transplantations have higher proportions of NKG2C+ 565 
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NK cells, there is no obvious change in NKG2C+ NK cells between patients with or 566 
without HCMV DNAemia 60 days after transplantation (42). In accordance with this, 567 
our results showed no differences between NKG2C+ and NKG2C- NK cell subsets in 568 
their ability to directly control HCMV dissemination (despite NKG2C expression 569 
being able to enhance CCL4 cytokine production), suggesting that there may not be a 570 
specific functional role for NKG2C in the direct control of HCMV. However, in light 571 
of recent published work suggesting the presence of HCMV seropositive-donor serum 572 
can induce stronger responses of NKG2Cbright NK cells in the short-term assay (44), 573 
it would be interesting to assess if the donor serum can influence the outcome of these 574 
long-term dissemination assays.  575 
 576 
In summary, we have presented here an improved, in vitro technique of assessing 577 
long-term immune control of NK cells against HCMV dissemination. Conventional 578 
NK cell cytotoxicity assays focus on the NK cell responses within a few hours of 579 
co-cultured with target cells. The VDA uses a much lower, more physiological E:T 580 
ratio than conventional NK cytotoxicity assays, and extends the analysis of NK cells 581 
responses to 9 days. Through the viral dissemination assay, we have uncovered new 582 
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evidence that NK cell subsets respond differently to different variants of viral ligands, 583 
but the expression of NKG2C made little difference to the outcome of the long-term 584 
HCMV control by NK cells. The VDA could be adapted to analyze other NK cell 585 
subsets that have been indicated as ‘memory-like’, and assess whether their in vitro 586 
control over virus spreading may be similar to that described previously for the 587 
murine Ly49H activating receptor and MCMV m157 protein (69). Taken together, 588 
this data is the first description of a number of novel interactions between NK cells 589 
and HCMV during long-term lytic lifecycles. These results may have implications for 590 
susceptibility to HCMV infection, and to future approaches to vaccination strategies 591 
that involve generation of immunological ‘memory-like’ responses of NK cells. 592 
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TABLE AND FIGURE LEGENDS 607 
Table 1: Primers used for UL18 mutant virus generation 608 
Sequences used to generate AD169-UL18 Merlin mutant virus are designated as 609 
Merlin-F (F: forward primer) and Merlin-R (R: reverse primer); Merlin-UL18AD 610 
Mutant virus are designated as AD169-F and AD169-R. Primer-F and Primer-R were 611 
used to amplify the a3 domain of HCMV UL18 protein in standard PCR. 612 
 613 
Figure 1– Establishment of viral dissemination assay. 614 
A) Human fibroblasts (HFFs) infected with HCMV strain TB40/e UL32-GFP at 615 
MOI= 0.1 and in vitro expanded NK cells were co-cultured for 9 days at various 616 
effector to target (E:T) ratios, starting from 1.25:1 to 0.3125:1, at 37°C and 5% CO2. 617 
NK cells were then washed off and the HFFs were observed by fluorescence 618 
microscopy (top panel) or following trypsinisation analysed by flow cytometry 619 
(bottom panel). Representative dot plots show the results from uninfected and 620 
infected controls and the change percentage of fluorescent cells following 621 
co-incubation with different ratios of NK cells: HFFs. B) The assay was also 622 
performed using HFFs infected with untagged AD169 at MOI=0.1. The cells were 623 
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stained intracellularly with anti-IE-Alexafluor488 antibodies before being analysed by 624 
flow cytometry. C) The summary results of dissemination assays on NK cells derived 625 
from N=7 donors using AD169 infected HFFs; from N=4 donors using TB40/e 626 
infected HFFs; and from N=9 donors using Merlin infected HFFs. MOI used was 0.1 627 
and various effector to target (E:T) ratios, starting from 1.25:1 to 0.3125:1, were used. 628 
At the end of the assay TB40/e-infected or Merlin-infected HFFs were analysed by 629 
flowcytometry without additional staining, while AD169-infected HFFs were stained 630 
with anti-IE-Alexafluor488 antibody before analysis by flowcytometry. Data was 631 
analysed by one-way ANOVA, and significant results (p<0.05 *, p<0.01**) are 632 
indicated. D) Three separate dissemination assays using HCMV strains AD169, 633 
TB40/e or Merlin at a MOI of 0.1 were conducted using in vitro expanded NK cells 634 
from either a seropositive (Donor 319) or a seronegative donor (Donor 401). The data 635 
was normalized according to the uninfected and infected controls. The black triangles 636 
are results from Merlin-infected HFF; grey triangles are TB40/e-infected HFF; and 637 
grey squares are AD169-infected HFF. Each data point represents 3 independent 638 
readouts, and error bars represent SEM. Data was analysed by two-way ANOVA, and 639 
significant results (p<0.05 *, p<0.01**) are indicated. 640 
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 641 
Figure 2– NK cells expressing LIR1 have similar effector cellular functions to 642 
LIR1 non-expressing NK cells, but are more able to control viral dissemination 643 
of HCMV strains TB40/e and Merlin.  644 
A) In vitro expanded NK cells were stained with anti-CD3, CD56 and LIR1 645 
antibodies and sorted by flow cytometry. CD56+ CD3- NK cells were first collected 646 
(NK) before further sorting into LIR1+ (LIR1+ NK) and LIR1- (LIR1- NK) subsets 647 
based on LIR1 expression. Representative dot plots of the NK cells before and after 648 
sorting are shown. B) NK, LIR1+ NK and LIR1- NK cells were co-cultured with 649 
K562 target cells. The NK cell to target ratio is 1:1. K562 cells and NK cells only are 650 
the controls. After culturing for 5 hours the percentage of CD107a+ cells were 651 
measured by flow cytometry. CCL4 concentration is quantified using ELISA after 652 
culturing overnight. Each data point represents the mean value of 3 repeats and error 653 
bars represent SEM. The experiment was preformed using three different donors 654 
(N=3) and the results showed the average value analysed by the Student T-test. Non- 655 
significant results (p>0.05, NS) is indicated. C) LIR1+ and LIR1- NK cell subsets 656 
were co-cultured with human HFFs infected with HCMV strain AD169, TB40/e or 657 
with Merlin at a MOI of 0.1 in a viral dissemination assay. The NK cell to target 658 
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ratios range from 1.25:1, 0.625:1 and 0.312:1. The data was normalized according to 659 
the uninfected and infected controls. The grey triangles are results from LIR- NK 660 
cells; and black squares are the results from LIR+ NK cells. Each data point 661 
represents 3 independent readouts, and error bars represent SEM. In total each assay 662 
was repeated three times (N=3) using NK cells from three different donors. Data was 663 
analysed by two-way ANOVA, and significant results (p<0.05*, p<0.01**) are 664 
indicated. 665 
 666 
Figure 3–UL18 proteins from different HCMV strains influence the control of 667 
virus dissemination by LIR1+ NK cells 668 
A) 67 sequences of HCMV UL18 proteins were identified from the NCBI protein 669 
database (www.ncbi.nlm.nlh.gov). 6 sequences had a truncation and are not included 670 
in the alignment. 13 unique amino acid sequences of the α3 region of UL18 were 671 
identified. Each unique sequence is only shown once in the alignment and is 672 
represented by a unique letter. The number following the letter in the sequence name 673 
represents the number of times the sequence has appeared in the database. Grey boxes 674 
indicate the sites interacting with LIR1 as suggested by crystal structure (57), while 675 
the black line indicates the key differences between the UL18 of AD169 and Merlin 676 
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strains. B) The results of the neighbour-phylogenic tree analysis showing the 677 
relationship between the sequences based on the protein α3 region. 20 virus strains 678 
have NKAPED sequence, 37 have DKVPED, and 4 have DKAPDD. C) NK cells 679 
from four different donors (N=4) were sorted based on LIR1 expression as previously 680 
described before co-cultured in a viral dissemination assay with HFFs infected with 681 
HCMV strain AD169 and AD169-ΔUL18 at an MOI of 0.1. Infected cells were 682 
stained with IE-ALEXA FLUOR 488 antibodies before analysis using flow cytometry. 683 
D) Viral dissemination assay was repeated with NK cells from four different donors 684 
(N=4) sorted based on LIR1 expression and co-cultured with HFFs infected with 685 
HCMV strain Merlin and Merlin-ΔUL18 at an MOI of 0.1. Infected HFFs were 686 
analysed on the basis of UL32-GFP fluorescence. In C) and D), the grey triangles are 687 
results from LIR- NK cells; black squares are the results from LIR+ NK cells. The 688 
NK cell to target ratios range from 1.25:1, 0.625:1 and 0.312:1. Each data point 689 
represents 3 independent readouts. The data was analysed using two-way ANOVA, 690 
error bars represent SEM and significant results (p<0.05*, p<0.01**) are indicated.  691 
 692 
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Figure 4–Mutation of HCMV UL18 proteins causes changes in the control of 693 
viral dissemination by NK cells. 694 
A) A PCR and sequencing on the α3 region of UL18 was preformed to check the 695 
mutant virus AD169-UL18Merlin and Merlin-UL18AD169 compared with parental 696 
strains. The amino acid alignment is shown with the altered sites indicated. Viral 697 
dissemination assays were then carried out using NK cell from four different donors 698 
(N=4) co-cultured with HFFs infected at MOI 0.1 with virus strains B) AD169 and 699 
AD169-UL18Merlin or C) Merlin and Merlin-UL18AD169 virus. AD169 and 700 
AD169-UL18Merlin infected HFFs were stained with IE-ALEXA FLOR 488 701 
antibodies before analysis using flow cytometry. Merlin and Merlin-UL18AD169 702 
virus infected HFFs expressed GFP and did not require additional staining. The NK 703 
cell to target ratios range from 1.25:1, 0.625:1 and 0.312:1. The grey triangles are 704 
results from LIR- NK cells; black squares are the results from LIR+ NK cells. Each 705 
data point represents 3 independent readouts. The data was analysed using two-way 706 
ANOVA, error bars represent SEM and significant results (p<0.05*, p<0.01**) are 707 
indicated.  708 
 709 
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Figure 5– Expression of NKG2C on in vitro expanded NK cells has an effect on 710 
NK cell effector functions. 711 
A) In vitro expanded NK cells were stained with anti-CD3, CD56 and LIR1 and 712 
NKG2C antibodies and sorted by flow cytometry into four subsets based on LIR1 and 713 
NKG2C expressions. CD56+ CD3- NK cells were first collected (NK) before further 714 
sorting into LIR1- NKG2C+, LIR1+ NKG2C+, LIR1- NKG2C- and LIR1+ NKG2C-. 715 
Representative dot plots of the NK cells before and after sorting are shown. Sorted 716 
NK cells were then co-cultured with B) K562 targets or C) HFFs infected with 717 
TB40/e at MOI of 5. The NK cell to target ratio is 1:1. The percentage CD107a+ cells 718 
were measured by flow cytometry after 5 hours, and the CCL4 cytokine secretion by 719 
NK cells were measured after overnight incubation. NK cell only and target cell only 720 
are the control samples. Error bars represent SEM. The experiment was repeated 721 
using 3 different donor NK cells (N=3) and the average results were analysed by the 722 
Student T-test. Significant results (p<0.05 *) are indicated.  723 
 724 
Figure 6– Expression of NKG2C on in vitro expanded NK cells does not control 725 
HCMV dissemination more effectively over long-term. 726 
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Viral dissemination assays were carried out using the NK cells sorted based on LIR1 727 
and NKG2C as previous described incubated with TB40/e-infected HFFs at an MOI 728 
of 0.1. The experiment was repeated four times using NK cells from four different 729 
donors. The NK cell to target ratios range from 1.25:1, 0.625:1 and 0.312:1. The 730 
results were analysed using flow cytometry and then normalized according to 731 
uninfected and infected controls. On each graph the circle represents LIR1 (+) 732 
NKG2C (+) NK cells; the rectangle represents LIR (+) NKG2C (-) NK cells; the 733 
upward triangle represents LIR1 (-) NKG2C (+) NK cells; and downward triangle 734 
represents LIR1 (-) NKG2C (-) NK cells. The comparison of LIR1 expressing and 735 
LIR1- non expressing subsets are shown in A); while the comparison of NKG2C 736 
expressing and NKG2C non-expressing subsets are shown in B). Each data point 737 
represents 3 independent readouts. The data was analysed using two-way ANOVA, 738 
error bars represent SEM and significant results (p<0.05*, p<0.01**) are indicated.  739 
 740 
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Table 1: Primers used for UL18 mutant virus generation 
Primer 
Names Sequence 
Merlin-F GACAACAGAGCTGAAGCATTCTGTACATCTTACGGGTTCTTTCCAGGGG 
AAATTAATATTACTTTTATCCATTACGGTCCTGTGACGGAAGATCACTTCG 
Merlin-R AAAAGATGGCTACGTAACATCCCTGATGGAAAGTCCCATCGAAGGTGG 
GAAGTAGCGGATTGCATTGAGGCTCGCTATCCTGAGGTTCTTATGGCTCTTG 
AD169-F GACAACAGAGCTGAAGCATTCTGTACATCTTACGGGTTCTTTCCAGGGG 
AAATTAATATTACTTTTATTCATTACGGTCCTGTGACGGAAGATCACTTCG 
AD169-R AAAAGATGGCTACGTAACATCCCTGATGGAAAGTCCCATCCAAGGTGG 
GAAGTAGCGGATTGCATTGAGGCTCGCTATCCTGAGGTTCTTATGGCTCTTG 
Primer-F AAACAAAACGTACATCGACGGTAA 
Primer-R AGCAAAGCGCATAAAAGCAGG 
 
 
